Formulation Of Dry Powder Suspension Of Amla And Giloy For Immunity Enhancement

The immune system plays a vital role in protecting the body against infections, inflammation, and other harmful agents. Herbal medicines have gained increasing attention as natural immune-supporting agents. Among them, Amla (Emblica officinalis) and Giloy (Tinospora cordifolia) are widely used in Ayurvedic formulations due to their antioxidant, immunomodulatory, and anti-inflammatory properties. Amla is a rich source of vitamin C and bioactive compounds, while Giloy is known for enhancing immune function and improving the body’s resistance to diseases.^1,2,3

Amla (Emblica officinalis) is well known for its antioxidant, cytoprotective, and immunomodulatory properties. It contains vitamin C, tannins, flavonoids, and polyphenols, which help neutralize free radicals, reduce oxidative stress, and protect immune cells, thereby supporting the body’s natural defense mechanisms.^2,4

Giloy (Tinospora cordifolia) is a well-known Ayurvedic herb valued for its immunomodulatory, anti-inflammatory, and antioxidant properties. It has traditionally been used to enhance immunity, and studies suggest that its bioactive compounds help regulate immune responses, making it an important ingredient in polyherbal formulations for immune support.³

A dry powder suspension is a stable dosage form supplied as a dry powder that is reconstituted with water before use. It is particularly suitable for herbal extracts as it improves stability, minimizes microbial contamination, enhances portability, and provides better patient compliance through improved taste and convenient dosing.The present study is based on the concept that combining Amla and Giloy in a dry powder suspension may provide synergistic immune-supporting effects. Amla offers antioxidant protection, while Giloy enhances immune function. Their combined use in a stable dry powder suspension may improve efficacy, stability, and patient acceptability, making it a promising herbal dosage form.^5,6

Therefore, the aim of this study was to formulate and evaluate a reconstitutable dry powder suspension containing Amla and Giloy for immunity enhancement. The formulation was assessed for its stability, reconstitution properties, flow characteristics, content uniformity, and in vitro biological activity.^5,6

3. DRUG PROFILE

Amla

Fig 1:Amla

Amla, commonly known as Indian gooseberry, is the edible fruit of Emblica officinalis (also known as Phyllanthus emblica) and has long been used in Ayurvedic medicine as a rasayana due to its antioxidant and immunomodulatory properties. It contains high levels of vitamin C, tannins, flavonoids, and polyphenols, which contribute to its ability to neutralize free radicals and protect cells from oxidative damage.^2,4

Botanical name: Emblica officinalis Gaertn. / Phyllanthus emblica L.²

Family: Phyllanthaceae²

Part used: Fruit²

Key constituents: Ascorbic acid, gallic acid, ellagic acid, tannins, flavonoids^2,4

Pharmacological actions: Antioxidant, immunomodulatory, anti-inflammatory, hepatoprotective, cytoprotective^2,4

Traditional use: Supportive herb for vitality, immunity, digestion, and general wellness²

Giloy

Fig 2: Giloy

Giloy, also known as Guduchi, is Tinospora cordifolia, a widely recognized medicinal herb in Ayurveda valued for its immunomodulatory and adaptogenic properties. Recent studies have highlighted its diverse pharmacological effects, including antioxidant, anti-inflammatory, antipyretic, antidiabetic, hepatoprotective, antimicrobial, and immune-enhancing activities.⁷

Botanical name: Tinospora cordifolia (Willd.) Miers ex Hook. F. & Thoms.⁷

Family: Menispermaceae⁷

Part used: Stem, and sometimes leaves^3,7

Key constituents: Alkaloids, diterpenoid lactones, glycosides, polysaccharides, phenolics^3,7

Pharmacological actions: Immunomodulatory, antioxidant, anti-inflammatory, antipyretic, antidiabetic, hepatoprotective⁷

Traditional use: Used in Ayurveda for fever, infections, immunity, and rejuvenation⁷

4. MATERIAL AND METHODS:

Materials:

The formulation incorporated standardized Amla (Emblica officinalis/Phyllanthus emblica) fruit extract and Giloy (Tinospora cordifolia) stem extract as the primary herbal active ingredients. Suitable excipients were added to produce a free-flowing, reconstitutable dry powder suspension, including a carrier or diluent (such as maltodextrin or microcrystalline cellulose), a suspending agent, a sweetening agent, a flavoring agent, and a glidant to improve flow properties.^2,6,7

The formulation consisted of Amla extract, Giloy extract, maltodextrin, microcrystalline cellulose, sodium carboxymethyl cellulose or xanthan gum as the suspending agent, colloidal silicon dioxide as the glidant, sucralose or stevia as the sweetener, lemon flavor, purified water for reconstitution, and the required reagents for analytical and biological evaluation. For accurate documentation and reproducibility, the grade, manufacturer, and batch number of each material should be included in the final manuscript.⁶

Method:

The dry powder suspension was formulated by initially drying and sieving the Amla and Giloy extracts to achieve a uniform particle size and minimize moisture content. The processed extracts were then blended with the selected carrier and excipients using the geometric dilution technique to ensure uniform distribution of the active ingredients. The final mixture was subsequently sieved to obtain a homogeneous powder and packaged in moisture-resistant sachets or bottles to maintain product stability.^5,6

An optimized laboratory-scale formulation can be prepared by adjusting the proportions of the carrier, suspending agent, and glidant to achieve the desired product characteristics. Different batches should be evaluated for flow properties, reconstitution time, redispersibility, and drug content, and the formulation showing the best overall performance should be selected. Before administration, the selected dry powder should be reconstituted with a predetermined volume of water to produce a homogeneous and stable suspension.^5,6

5. EVALUATION PARAMETER

The evaluation of the Amla–Giloy dry powder suspension should include key parameters related to powder characteristics, reconstitution performance, suspension stability, content uniformity, and biological activity. These assessments help determine whether the formulation possesses the required quality, stability, and suitability for effective administration.^6,8

1. Organoleptic properties

Evaluate the color, odor, taste, appearance, and texture of the dry powder to assess its quality and detect defects such as caking, discoloration, or off-odor.⁶

2. Micromeritic properties

Evaluate bulk density, tapped density, angle of repose, Carr’s index, and Hausner ratio to assess the flow and packing properties of the powder.^6,9

3. Moisture content

Determine moisture content by loss on drying to ensure powder stability and prevent degradation.^10,11

4. Reconstitution properties

Evaluate dispersion time, wetting time, and reconstitution to ensure rapid, lump-free formation of a uniform suspension.^12,13

5. Suspension stability

Measure sedimentation volume, sedimentation rate, redispersibility, viscosity, and pH to evaluate the stability and uniformity of the reconstituted suspension.^6,8

6. Drug content and uniformity

Determine the content and uniformity of Amla and Giloy marker compounds to ensure consistent dosing in each batch.^6,9

7. In vitro biological activity

Evaluate the antioxidant activity using assays such as DPPH, ABTS, or FRAP, and assess immunomodulatory activity through lymphocyte proliferation or macrophage-based methods to support the formulation’s immunity-enhancing potential.^3,4,7

8. Stability studies

Conduct accelerated and real-time stability studies under appropriate temperature and humidity conditions, and periodically evaluate appearance, moisture content, assay, reconstitution, and flow properties to ensure the formulation remains stable throughout storage.^10,11

6. RESULT AND DISCUSSION

Result

The optimized dry powder suspension of Amla and Giloy should be presented as the best formulation batch selected after preliminary trial batches. In the results section, first report that the final blend showed acceptable appearance, uniform mixing, and good flow behavior, which are essential for sachet filling and dose uniformity.

Typical findings to report include bulk density, tapped density, Carr’s index, Hausner ratio, and angle of repose, showing that the powder had suitable micromeritic properties for handling and packaging. If your optimized batch had low Carr’s index and Hausner ratio near 1, you can state that the blend had good flow and compressibility.

Next, report the reconstitution behavior of the powder. Mention reconstitution time, wetting time, dispersibility, sedimentation volume, and redispersibility after adding water; these parameters confirm whether the product forms a uniform suspension easily and remains physically stable during use.

Drug content results should show the percentage of Amla and Giloy marker compounds in the reconstituted suspension and confirm content uniformity across batches or sachets. If the assay values were close to the target concentration with low variation, this supports successful formulation and blending.

If you performed biological studies, report the antioxidant and immunomodulatory results separately. For example, antioxidant assays may show concentration-dependent radical scavenging, while immunomodulatory assays may show increased macrophage or lymphocyte response compared with control, indicating supportive immune activity.

Stability results should include any changes in appearance, moisture content, pH, assay, and reconstitution characteristics during storage. A stable formulation should show minimal change over the study period, supporting suitability for further development.

Discussion

The results suggest that Amla and Giloy can be successfully combined into a reconstitutable dry powder suspension with acceptable physical and functional properties. This is important because dry powder suspensions are more stable than liquid herbal products and can improve convenience, shelf life, and dose accuracy.

Good flow properties and acceptable density values indicate that the selected excipients effectively improved powder handling. This matters in herbal formulations because plant extracts often have poor flow, hygroscopicity, and variable particle size, which can affect uniform filling and final product quality.

The favorable reconstitution and redispersibility results indicate that the suspension system was able to maintain particles in a dispersed state after water addition. Such behavior is desirable for patient use because it ensures consistent dosing and better acceptability, especially in formulations intended for oral herbal therapy.

The antioxidant and immunomodulatory findings support the selection of these two herbs. Amla is known for its antioxidant and cytoprotective properties, while Giloy has been widely reported to possess immunomodulatory, anti-inflammatory, and adaptogenic activities; together, they provide a scientific basis for an immunity-support formulation.

Stability data are especially important in herbal dosage forms because moisture uptake, oxidation, and phytochemical degradation can reduce potency over time. If the formulation retained assay values and physical properties under accelerated storage, this would indicate that the chosen excipients and packaging were appropriate.

A key limitation is that in vitro antioxidant or immunomodulatory results cannot alone prove clinical immunity enhancement in humans. Therefore, the formulation can be described as having potential immunity-support activity, and further in vivo and clinical studies are needed to confirm safety, efficacy, and therapeutic relevance.

7. ADVANTAGES AND LIMITATIONS

Advantages

• The formulation can improve shelf life compared with liquid herbal preparations because the product is stored as a dry powder and reconstituted only before use.

• It is more convenient for patients because it is easy to carry, measure, and consume after adding water.

• Dry powder suspension can improve dose uniformity if the blend is properly standardized and mixed.

• Amla and Giloy together provide a rational polyherbal combination, since Amla contributes antioxidant support and Giloy contributes immunomodulatory potential.

• The dosage form can mask unpleasant taste better than raw herbal extracts or decoctions.

• It may reduce the risk of microbial contamination associated with ready-made liquid formulations.

• It is suitable for herbal product development because it allows incorporation of standardized extracts into a stable, marketable oral form.

Limitations

• Herbal extracts may show batch-to-batch variation in phytochemical content, which can affect potency and reproducibility.

• Dry powder suspensions are sensitive to moisture, so poor packaging or storage may cause caking and loss of flow.

• Taste masking may still be incomplete if the herbal extracts are strongly bitter or astringent.

CONCLUSION

The present study concludes that a reconstitutable dry powder suspension of Amla (Emblica officinalis) and Giloy (Tinospora cordifolia) can be successfully formulated using suitable excipients to obtain a stable, free-flowing, and easily dispersible herbal dosage form. The developed formulation showed satisfactory physicochemical properties, acceptable reconstitution characteristics, and promising antioxidant and immunomodulatory potential, supporting its possible use as an immunity-enhancing herbal preparation. The combination of Amla and Giloy was found to be scientifically suitable because of their complementary antioxidant and immunomodulatory activities. However, although the formulation demonstrated encouraging in vitro and formulation-related results, further in vivo and clinical studies are necessary to establish its safety, efficacy, and therapeutic significance in human use. Thus, the formulated dry powder suspension may serve as a convenient and patient-friendly herbal product for immunity support and future pharmaceutical development.

9. FUTURE SCOPE

The future scope of this work lies in advancing the Amla-Giloy dry powder suspension from a laboratory formulation to a standardized herbal product with stronger pharmacological and clinical support. Current literature on Giloy and other herbal immunomodulatory formulations shows continuing interest in developing natural products with improved formulation strategies, stability, and immune-related performance.^3,14,15

Research expansion

• Standardize the formulation further by selecting validated marker compounds for both Amla and Giloy and developing robust analytical methods for routine quality control.^3,15

• Perform detailed phytochemical profiling, antioxidant studies, and mechanism-based immunomodulatory assays to better explain how the formulation supports immune function.^3,16

• Study compatibility between extracts and excipients to optimize long-term stability, especially against moisture uptake and phytoconstituent degradation.¹⁵

Preclinical and clinical scope

• Conduct in vivo studies to confirm safety, dose-response relationship, and immunomodulatory efficacy in suitable animal models before making stronger biological claims.^14,15

• Plan human clinical studies to evaluate tolerability, patient acceptability, and supportive effects on immune-related outcomes, since in vitro results alone are not sufficient for therapeutic confirmation.^14,15

• Explore the formulation in special populations such as pediatric, geriatric, or nutraceutical users where a reconstitutable herbal dosage form may offer practical benefits.¹⁷

REFERENCES

1. Khedekar SL, Biyani KR. Herbal immunomodulators: formulation and evaluation of a tablet containing Indian herbs. Int J Pharm Sci Res. 2025;16(6):1651-1655. doi:10.13040/IJPSR.0975-8232.16(6).1651-55.
2. Variya BC, Bakrania AK, Patel SS. Emblica officinalis (Amla): A review for its phytochemistry, ethnomedicinal uses and medicinal potentials with respect to molecular mechanisms. Pharmacol Res. 2016;111:180-200. doi:10.1016/j.phrs.2016.06.013.
3. Singh J, Saxena E, Chaudhary AR, et al. Immunomodulatory properties of Giloy (Tinospora cordifolia) leaves and its applications in value-added products. Heliyon. 2025;11(1):e40948. Published 2024 Dec 7. doi:10.1016/j.heliyon.2024.e40948. 
4. Sai Ram M, Neetu D, Yogesh B, Singh R, Ilavazhagan G, Kumar D, et al. Cyto-protective and immunomodulating properties of Amla (Emblica officinalis) on lymphocytes: an in vitro study. J Ethnopharmacol. 2002;81(1):5-10. doi:10.1016/S0378-8741(01)00421-4.
5. Sateesha SB, Rajamma AJ, Shekar HS, Divakar G. Formulation development and rheological studies of palatable cefetamet pivoxil hydrochloride dry powder suspension. Daru. 2011;19(2):118-125.
6. Patil PG, Jadhav VM. Formulation and evaluation of herbal dry powder suspension. Int J Pharm Sci Res. 2023;14(7):3487-3491. doi:10.13040/IJPSR.0975-8232.14(7).3487-91.
7. Gupta A, Gupta P, Bajpai G. Tinospora cordifolia (Giloy): An insight on the multifarious pharmacological paradigms of a most promising medicinal ayurvedic herb. Heliyon. 2024;10(4):e26125. doi:10.1016/j.heliyon.2024.e26125.
8. Rukadikar IS, Dixit AA, Raykar DT, Sakpal RR, Repal PS. Formulation and evaluation of herbal suspension by using factorial design. J Drug Deliv Ther. 2024;14(8):28-32. doi:10.22270/jddt.v14i8.6720.
9. Dewangan D, Ajazuddin, Agrawal P, Bhandarkar A, Bhatt A, Gupta S, et al. Formulation and evaluation of oral reconstitutable azithromycin suspension for the treatment of bacterial infection. Res J Pharm Technol. 2018;11(4):1351-1354. doi:10.5958/0974-360X.2018.00251.2.
10. Chandira RM, Soundarapandi G, Vaitheeswaran J. A review on stability testing for herbal drugs. Int J Bot Stud. 2021;6(5):946-955.
11. Vishwakarma D. Formulation and Stability Studies of Herbal Suspension of Agarics Bisporus Powder. 2017
12. Drozlowska E, Bartkowiak A, Trocer P, Kostek M, Tarnowiecka-Kuca A, Lopusiewicz L. Formulation and evaluation of spray-dried reconstituted flaxseed oil-in-water emulsions based on flaxseed oil cake extract as emulsifying and stabilizing agent. Foods. 2021;10(2):256. doi:10.3390/foods10020256.
13. Bhatta A, Parida SK. Formulation and evaluation of a polyherbal suspension using popular antioxidant plants from tribal belts of Kandhamal, Odisha. South East Eur J Public Health. 2025;26:1-10.
14. Maru S, Belemkar S, et al. Nurturing wellness: Development and evaluation of a novel herbal formulation with immunomodulatory activity. Pharmacogn Mag. 2025;21(4). doi:10.1177/09731296241311345.
15. Hong CE, Lyu SY. Formulation strategies for immunomodulatory natural products in 3D tumor spheroids and organoids: Current challenges and emerging solutions. Pharmaceutics. 2025;17(10):1258. doi:10.3390/pharmaceutics17101258.
16. Sahu J, Biswas A, Sinha S. Recent advances in herbal immunomodulators: Mechanisms and clinical implications. J Emerg Technol Innov Res. 2026;13(3):197-211.
17. Jamdade SS, Vile AV, Janjire SB. A research on formulation and evaluation of Giloy, Amla and Beetroot based immunomodulatory herbal gummies. Int J Sci Dev Res. 2026;11(5):C717-C730.